Compare
Zepbound vs. Wegovy

Zepbound (tirzepatide) is an injectable medication that's used along with diet and exercise. It helps with weight loss in adults who meet criteria for weight management therapy. It's also approved to treat moderate-to-severe sleep apnea. This medication belongs to the drug class called GIP and GLP-1 agonists. The dosage is 1 injection under the skin once a week. Common side effects include nausea, diarrhea, and injection site reactions. Zepbound (tirzepatide) is only available as a brand-name medication.

In addition to a balanced diet and exercise plan:

• Weight loss and long-term weight management in adults considered obese or overweight with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes)
• Moderate-to-severe obstructive sleep apnea (OSA) in adults considered obese

• Nausea (25-29%)
• Diarrhea (19-23%)
• Constipation (11-17%)
• Vomiting (8-13%)
• Stomach pain (9-10%)
• Indigestion (9-10%)

• Risk of thyroid cancer
• Stomach problems
• Kidney damage
• Gallbladder problems
• Inflammation of the pancreas (pancreatitis)
• Allergic reactions
• Low blood sugar (hypoglycemia)
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Lung problems during general anesthesia or deep sedation
• Don't share Zepound KwikPens with anyone

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It comes in prefilled pens you use to inject the medication under the skin once a week. Wegovy (semaglutide) also comes as tablets that are swallowed once a day. This medication is approved for weight loss in some people. It can help lower the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease. The pens are also approved for certain adults with a liver problem called metabolic dysfunction-associated steatohepatitis (MASH). The medication works best when taken with a lower-calorie diet and regular exercise. Side effects include nausea, diarrhea, and stomach pain.

Injectable pens:

• Weight loss and long-term weight management in:

  • People ages 12 years and older who are considered obese
  • Adults considered overweight with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes, high cholesterol)

• Lowering the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease

• Metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver scarring, but not cirrhosis

Tablets:

• Weight loss and long-term weight management in adults who are considered obese or overweight with at least one weight-related condition
• Lowering the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Stomach pain (20%)
• Headache (14%)
• Tiredness (11%)

• Possible risk for thyroid cancer
• Inflammation of the pancreas (pancreatitis)
• Gallbladder problems
• Low blood sugar
• Kidney damage
• Allergic reactions
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Faster heart rate
• Lung problems during general anesthesia or deep sedation